AWC Berhad - Shah Alam Hospital HSS Contract Extended, Worth RM26.14m
Wed, 18-Mar-2026 07:58 am
by Research Team • Apex Research

Counter

AWC (7579)

Target Price (RM)

0.60

Recommendation

Buy

  • AWC has secured a contract extension with a value of RM26.14m (1-year extension) this continues AWC's decade-long incumbency at Hospital Shah Alam, reinforcing the depth and stickiness of its Healthcare Support portfolio within the Facilities division.

  • Applying a 4% PBT margin, the extension is estimated to generate ~RM1.05m in PBT – equivalent to approximately 3.6% of our FY26F Group PBT of RM29.5m.

  • No changes to our earnings forecasts. We remain cautiously optimistic on the overall outlook, mindful of geopolitical headwinds from the ongoing Iran conflict which could prolong Middle East softness and weigh on the Environment division's bottom line.

  • Upgrade to BUY with an unchanged TP of RM0.60, based on 9x FY26F EPS of 6.6 sen, on the back of the recent share price weakness, supported by a three-star ESG rating.

     

RM26.14m Shah Alam Hospital Extension. AWC has maintained a long-standing operational presence at Hospital Shah Alam since the facility first commenced operations in 2016. Following the initial award, AWC successfully secured a five-year competitive contract worth RM107.89 million via an open tender from the Ministry of Health (MoH) for the period January 2021 to December 2025. The current extension, announced on March 17, 2026, extends AWC's HSS provision for a further year at a contract value of RM26.14m (via its wholly owned subsidiary, Ambang Wira Sdn Bhd)The contract extension value of RM26.14m implies an annualized run rate significantly above the previous five-year average of RM21.58m p.a., suggesting that the bridge extension incorporates cost adjustments for inflation and minimum wage increases pending a new long-term tender.

 

Our Take. Positive on incumbency; modest but visible PBT uplift. We view this contract extension positively. It underscores AWC's ability to retain healthcare mandates through operational excellence and reinforces the predictability of its facilities division revenue stream. Hospital Shah Alam is a strategically important site within AWC's Healthcare Support portfolio, sitting alongside key anchors such as the National Cancer Institute (IKN) and the National Institute of Health (NIH). PBT Impact. Applying a conservative 4% PBT margin, the RM26.14m extension is expected to contribute c.RM1.05m in PBT over the next year. This represents approximately 3.6% of our FY26F Group PBT forecast of RM29.5m, a modest and visible contribution from a single-site contract. The Facilities Division remains the anchor as it is AWC's largest revenue contributor, accounting for ~50% of 1HFY26 revenue (RM115.8m). The division delivered a 154.3% QoQ PBT jump in 2QFY26 to RM1.0m, supported by a 15.5% revenue increase from the facilities segment. The Hospital Shah Alam extension further bolsters this positive trajectory, AWC's Facilities order book stands at RM465m (51.1% of the group's RM910m backlog), providing multi-year earnings visibility.

 

Outlook. We expect steady earnings growth in 2HFY26 as revenue recognition ramps up from high-value Facilities wins, including TM Data Centres (RM99.1m), Kompleks E (RM82.5m), Masjid Putra (RM52.3m), and the recent Hospital Shah Alam extension (RM26.14m). This recovery is supported by concession extensions at revised market rates, a strategic push into high-tech FM, and the Engineering division's plumbing growth. The Environment segment’s record RM224m order book and the ramp up of Singapore’s mandated PWCS pipeline in 2H26 is expected to provide a structural earnings floor. However, the Middle East remains a lingering overhang; ongoing Iran-related conflict and geopolitical tensions risk further delaying projects in Abu Dhabi and Dubai, potentially sustaining the 64.9% YoY revenue contraction seen in 1HFY26. Despite these regional risks, a strengthened Group order book of c.RM910m and the Rail division’s 1.5x QoQ order book jump to RM106m positions the Group favourably for FY27, maintaining a cautiously optimistic outlook anchored by stable, service-based recurring income.

 

Earnings revision. We are comfortable with our current assumptions, and this contract extension falls within our FY26F Facilities revenue estimates. While the RM26.14m HSS extension provides an incremental ~RM1.05m PBT uplift (4% margin), it does not materially alter our full-year projections. As such, we retain our FY26F–FY28F revenue forecasts.

 

Valuation. We upgrade to a BUY recommendation following the recent share price weakness with an unchanged TP of RM0.60, based on 9x FY26F EPS of 6.6 sen and a three-star ESG rating. We like AWC for its (i) dominant market position (90% AWS share in Malaysia, 40% in Singapore), (ii) predictable cash flows from long-term concessions, (iii) strengthened order book of RM910m (2.2x FY25 revenue), and (iv) a clean net cash balance sheet. At current prices, the stock trades at 7.8x FY26F P/E - offering limited downside with a 1.7% dividend yield.

 

Risks. Failure to secure improved rates for government concession contracts under the IFM segment, continued softness in the Middle East affecting the Environment Division contributions, and failure to maintain margin resilience and weaker orderbook replenishment in the Rail segment following recent declines in product mix profitability.

Read more details in:

Disclaimer

The report is for internal and private circulation only and shall not be reproduced either in part or otherwise without the prior written consent of Apex Securities Berhad. The opinions and information contained herein are based on available data believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell the securities covered by this report.

Opinions, estimates and projections in this report constitute the current judgment of the author. They do not necessarily reflect the opinion of Apex Securities Berhad and are subject to change without notice. Apex Securities Berhad has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Apex Securities Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Apex Securities Berhad. Apex Securities Berhad may from time to time have an interest in the company mentioned by this report. This report may not be reproduced, copied or circulated without the prior written approval of Apex Securities Berhad.

Market Mover
Settlement Rates
Currency Buy Rates (RM) Sell Rates (RM)
USD 3.939468 3.970256
EUR 4.653745 4.662279
CNY 0.579514 0.580003
HKD 0.503483 0.506935
SGD 3.096378 3.120719